Table 4 GDT utilized based on NGS results (n = 15)
Patient | Tumor Type | Targeted Genetic Alterations | Therapy | Duration of benefit (months) | Best Response after GDT |
|---|---|---|---|---|---|
1 | Cholangiocarcinoma | BRAFV471F, EGFR T790 M | Sorafenib | 0 | PD |
2 | Breast cancer, recurrence | AKT3 amplification, PIK3R1 F456_E458del, PTEN loss exon 3 | Everolimus | 0 | PD |
3 | NSCLC, squamous with sarcomatous features | KRAS G13D | Trametinib | 0 | PD |
4 | Head and neck squamous cell carcinoma | EGFR amplification | Cetuximab | 0 | PD |
5 | NSCLC, adenocarcinoma | NRAS Q61K | Trametinib | 5 | SD |
6 | Breast cancer | PIK3R1 K448_Y452del | Everolimus | 0 | PD |
7 | Osteosarcoma | CCND3 amplification, CDK4 amplification | Palbociclib | 0 | PD |
8 | Anaplastic astrocytoma | BRAFV600E (HGF amplification) | Vemurafenib | 6 | SD |
9 | Large cell neuroendocrine carcinoma | PTEN N323 fs*2 | Everolimus | 0 | PD |
10 | Cholangiocarcinoma | IDH2 R172K | AG-881 (IDH inhibitor) | 0 | PD |
11 | Esophageal carcinoma | PIK3CA R88Q, STK11 loss | Everolimus | 0 | PD |
12 | Gastric adenocarcinoma | FLT3 amplification | Sorafenib | 2 | SD |
13 | NSCLC, squamous | HGF amplification | Crizotinib | 0 | PD |
14 | GE junction adenocarcinoma | VEGFA amplification | Sorafenib | 0 | PD |
15 | Adrenal cortical cancer | TP53 H179R | AZD1775 (WEE1 kinase inhibitor) | 0 | PD |